Pegasys® (peginterferon alfa-2a): supply shortage of 90/135/180 micrograms solution for injection in pre-filled syringes.

Increased overall demand for Pegasys (peginterferon alfa-2a) has led to an intermittent shortage of all approved strengths (90/135/180 micrograms) of Pegasys. The supply shortage is not related to a quality defect of the product or a safety issue.

Pharma& anticipates the shortage to last until the second half of 2025; additional product is currently estimated to be supplied before June 30, 2025.

During the supply shortage prescribers are advised to follow the below recommendations:

• No new patients should be started on Pegasys until supply has normalised. Available product should only be used to continue treatment of patients currently treated.
• In case Pegasys is not available for patients currently under treatment, alternative treatment options should be considered based on your clinical judgement.
• Always store supplies in the fridge and use the most appropriate strength to avoid wastage.